PhaseBio Pharmaceuticals, Inc.
Case Number:
1:22-bk-10995
Court:
Nature of Suit:
Firms
- Armstrong Teasdale
- Bielli & Klauder
- Buchalter APC
- Buchanan Ingersoll
- Chipman Brown
- Cooley LLP
- Covington & Burling
- Goodwin Procter
- Ice Miller
- Keating Muething
- Klehr Harrison
- K&L Gates
- Lewis Brisbois
- Lowenstein Sandler
- Maron Marvel
- McCarter & English
- McDermott Will & Emery
- Miller & Martin
- Morris James
- O'Melveny & Myers
- Orrick Herrington
- Porzio Bromberg
- Potter Anderson
- Richards Layton
- Seyfarth Shaw
- Venable LLP
- Womble Bond
Companies
- Certara USA Inc.
- Chiesi Farmaceutici SpA
- KPMG International
- MedImmune LLC
- Miller Buckfire & Co. LLC
- Oracle Corp.
- PhaseBio Pharmaceuticals Inc.
- Synchrogenix
Sectors & Industries:
-
June 26, 2024
Pharma Co. PhaseBio Can Exit Ch. 11 With Wind-Down Plan
A Delaware bankruptcy judge on Wednesday gave her blessing for pharmaceutical developer PhaseBio Pharmaceuticals Inc. to liquidate its assets and wind down after settlement agreements with creditors and a business partner cleared a path for it to exit Chapter 11 after roughly 19 months.
-
February 06, 2023
PhaseBio Suitor Gets $2M Breakup Fee Without Ch. 11 Auction
An Italian pharmaceutical company chosen to serve as a bidder-to-beat for a later-canceled Delaware Chapter 11 auction of drug research firm PhaseBio Pharmaceuticals still deserves a $2 million breakup fee based on the proposal's benefit to the estate, a bankruptcy judge ruled on Monday.
-
January 17, 2023
Pharma Co. Seeks $2M Fee For Bid In Canceled Ch. 11 Auction
An Italian pharmaceutical company told a Delaware bankruptcy judge Tuesday that it is entitled to a $2 million fee for submitting an unsuccessful baseline bid for a bankrupt drug research firm even though the company chose a settlement instead of going through with the asset sale.